NVAX Q1 2022 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$605M+35.2% YoY

Gross Profit

$589M97.5% margin

Operating Income

$209M34.6% margin

Net Income

$203M33.6% margin

EPS (Diluted)

$2.52

QoQ Revenue Growth

+183.2%

Cash Flow

Operating Cash Flow

-$89M

Free Cash Flow

-$105M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$2.8B

Total Liabilities

$2.8B

Stockholders' Equity

$65M

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$605M	$447M	+35.2%
Gross Profit	$589M	$447M	+31.8%
Operating Income	$209M	-$209M	+200.3%
Net Income	$203M	-$223M	+191.3%

Revenue Segments

Product

$586M83%

Grant

$99M14%

Royalties and Other

$19M3%